Effect of Add-on Montelukast to Inhaled Corticosteroids on Airway Responsiveness

• Status: Completed
• Trial end date: 2006-10-01
• Target enrollment: 0
• Participant gender: All

Summary

Leukotriene receptor antagonists appear to posses additive anti-inflammatory effects to the effect of inhaled corticosteroids.

Hypothesis: Treatment with oral montelukast will lower the dose-response plateau to inhaled methacholine in patients with mild to moderate persistent asthma treated with a stable dose of inhaled corticosteroids.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Hvidovre University Hospital
• Treatments: Montelukast

Criteria

Inclusion Criteria:

• Non-smoking adults with mild to moderate persistent asthma:

• FEV1 > 70 % pred

• PD20 methacholine < 3.9 mmol

• treated for at least 3 months with a stable dose of inhaled corticosteroids

• Documented dose-response plateau to inhaled methacholine on two occasions

• Males and non-pregnant females

Exclusion Criteria:

• Asthma medication other than inhaled corticosteroids and inhaled b2-agonists

• Viral respiratory tract infections within the 3 weeks prior to enrollment